Orthocell (ASX:OCC) shares were trading up 12% intra-day today at A$0.65, after the regenerative medicine company confirmed its “cell factory” intellectual property as valid for the growth of cartilage and bone.
The twelve month range is $0.275 to $0.99.
Data from a successful study on the bioactive molecules follows Cell Factory work for cartilage injuries announced by Orthocell in May.
The technique is expected to represent a clinically effective and cost effective approach to treating unhealed factures, one of the most difficult orthopaedic conditions.
The research, however, does not relate to Orthocell’s primary product focuses, which are the development of a stem cell treatment for the regeneration of human tendon tissue and the development of collagen based scaffolds for the reconstruction and regeneration of soft tissue injuries within the body.
Share pricing for the company was also supported in July by progress demonstrating that growth factors derived from cells cultivated in a controlled cell factory regenerated articular cartilage defects in a rabbit animal model.
Steps forward with the cell factory method are part of Orthocell’s focus on pursuing growth and commercialisation opportunities with a number of third parties.
In March, the company received ethical approval from St John of God Hospital Subiaco in Western Australia for a pilot clinical study for its Celgro collagen scaffold. The study is meant to demonstrate that Celgro can be used as a barrier membrane to allow bone growth without competition from other connective tissue.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.